Combined PET and Blood Tests Predict Lymphoma Relapse Risk with 85% Accuracy

This breakthrough study addresses a critical challenge in follicular lymphoma care: identifying patients at high risk of early disease progression who might benefit from more aggressive treatment approaches.

Researchers analyzed data from 141 patients in the RELEVANCE phase 3 trial, combining PET imaging with circulating tumor DNA analysis at the end of initial treatment. They used a sophisticated 130-kilobase DNA capture panel to detect tumor-specific genetic variants in blood samples.

The results were striking. Patients with undetectable tumor DNA after treatment had dramatically longer progression-free survival compared to those with detectable DNA (median not reached vs 17.7 months). Similarly, patients with negative PET scans fared much better than those with positive scans.

The real breakthrough came from combining both tests. While each test alone had over 90% negative predictive value for early progression, their positive predictive values were modest (58.3% for DNA, 45% for PET). However, when both tests were positive, the positive predictive value jumped to 85.7% without compromising the excellent negative predictive value.

This combination approach could revolutionize treatment decisions in follicular lymphoma. Currently, about 12% of patients experience progression within 24 months of diagnosis, which correlates with significantly worse survival outcomes. Early identification of these high-risk patients could enable preemptive treatment strategies, potentially improving long-term outcomes and quality of life for this vulnerable population.